Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO is a phase 3, randomised interventional study registered as NCT05078047 by UNICANCER, with a registry enrolment figure of 646 participants, started 2022-03-08 and due to reach its primary completion in 2029-05-07. Interventions recorded: Reduced dose intensity of IO. Conditions listed: Lung Cancer Metastatic; Renal Cell Carcinoma; Head and Neck Cancer; Triple Negative Breast Cancer; Merkel Cell Carcinoma; Hepatocellular Carcinoma; Melanoma; Urothelial Carcinoma; Colorectal Carcinoma With Microsatellite Instability; Esophageal Squamous Cell Carcinoma; Endometrial Carcinoma; Cervical Cancer; Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinoma; Basal Cell Carcinoma; Squamous Skin Carcinoma. Triple-negative eligibility wording from the registry: "Metastatic disease (or locally advanced disease not suitable for local treatment) of initial tumor histologically confirmed including: lung cancer, renal cell cancer, head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, hepatocellular carcinoma, melanoma, colorec". Sites: France. No results are recorded here; the registry entry is the source.